What is Epicore Biosystems?
Epicore Biosystems operates at the intersection of biotechnology and consumer electronics, specializing in the development of advanced sweat-sensing wearables. These devices provide users with real-time, personalized health insights, focusing on critical metrics such as hydration levels, stress, and overall wellness. By integrating clinically validated biowearable hardware with sophisticated cloud-based analytics, the company offers a comprehensive solution for health monitoring.
The firm's market position is solidified by its diverse client base, which includes Fortune 500 corporations, the Department of Defense, and the National Institute of Health. This broad adoption across both commercial and governmental sectors highlights the versatility and reliability of Epicore's technology. As the demand for actionable health data continues to rise, Epicore Biosystems remains uniquely positioned to capitalize on the shift toward proactive, data-driven personal health management.
How much funding has Epicore Biosystems raised?
Epicore Biosystems has raised a total of $42.5M across 4 funding rounds:
Angel/Seed
$350K
Debt
$150K
Series A
$10M
Series B
$32M
Angel/Seed (2018): $350K with participation from Social Starts
Debt (2020): $150K led by PPP
Series A (2022): $10M supported by Joyance Partners, Chevron Technology Ventures, and Alumni Ventures
Series B (2025): $32M featuring Joyance Partners and Alumni Ventures
Key Investors in Epicore Biosystems
Joyance Partners
Joyance invests in companies that leverage science and technology to enhance quality of life across North America, Europe, and Asia, focusing on health and consumer sectors.
Alumni Ventures
Alumni Ventures Group creates and manages alumni venture capital funds at top colleges and universities, providing a structured playbook for early-stage and growth-stage investments.
Social Starts
Social Starts is a venture capital partnership specializing in moment-of-inception and Series A financing, with a specific focus on startups that enhance quality of life and longevity.
What's next for Epicore Biosystems?
With the successful closure of this latest financing round, Epicore Biosystems is well-positioned to accelerate its commercial deployment and enhance its data analytics infrastructure. The strategic focus will likely shift toward expanding the reach of its biowearable platforms into new international markets and deepening its integration with existing enterprise health ecosystems. By leveraging the expertise of its investor base, the company aims to refine its clinical validation processes and broaden the scope of its physiological monitoring capabilities.
Looking ahead, the company is expected to prioritize the scaling of its manufacturing and distribution networks to support the increasing requirements of its institutional partners. As Epicore Biosystems continues to innovate, the integration of advanced machine learning models into its cloud analytics platform will be pivotal in delivering more precise, predictive health insights. This strategic roadmap ensures that the company remains a dominant force in the evolving landscape of digital health and wearable technology.
